Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways-Reference-Cited by-同舟云学术

Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways

Published:2014-10-04 Issue:5 Volume:168 Page:765-768
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Zhao Xiaoxian¹,Bodo Juraj¹,Sun Danyu²,Durkin Lisa¹,Lin Jeffrey¹,Smith Mitchell R.²,Hsi Eric D.¹

Affiliation:

1. Department of Laboratory Medicine; Robert J. Tomsich Pathology and Laboratory Medicine Institute; Cleveland Clinic; Cleveland OH USA

2. Department of Hematology and Oncology; Taussig Cancer Institute; Cleveland Clinic; Cleveland OH USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13149/fullpdf

Reference10 articles.

1. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma;Axelrod;Leukemia,2014

2. B cell receptor-induced cAMP-response element-binding protein activation in B lymphocytes requires novel protein kinase Cdelta;Blois;Journal of Biological Chemistry,2004

3. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation;Chen;Cancer Research,2007

4. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma;Davis;Nature,2010

5. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma;Fresquet;Blood,2014

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis;Blood Advances;2024-08-29

2. Ready, AIM, stop: ibrutinib plus venetoclax in MCL;Blood;2024-08-22

3. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions;Blood;2024-08-22

4. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma;International Journal of Clinical Oncology;2023-12-29

5. Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents;Journal of Hematology & Oncology;2023-08-25